Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Brello Health

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Brello Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 388 · Grade C

Brello Health

Visit Brello Health Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 58 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Brello Health a bad call — it's best for people comparing prepaid compounded injections who understand eleven-week billing, pharmacy assignment and the distinct refund deadlines. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
28
Supply Reliability
95
73
Transparency
90
63
Access Breadth
93
54
Clinical Oversight
92
72
Track Record
88
74
CoreAge RxBrief Score 94 · 58Brello Health

Price, coverage & the tracker

CoreAge RxBrello Health
Brief Score94/100 (A)58/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$399 upfront

Advertised three-month plan; renews $399 every 11 weeks.

Supplies, review and shipping included; selected quote and eligibility need confirmation.

Full price details

Compounded semaglutide injection offered; complete selected-prescription quote unknown; $399 upfront for advertised 3-month plan, renews $399 every 11 weeks, displayed $133/month equivalent; pharmacy and state eligibility apply

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$499 upfront

Advertised three-month plan; renews $499 every 11 weeks.

Supplies, review and shipping included; selected quote and eligibility need confirmation.

Full price details

Compounded tirzepatide injection offered; complete selected-prescription quote unknown; $499 upfront for advertised 3-month plan, renews $499 every 11 weeks, displayed $166/month equivalent; pharmacy and state eligibility apply

CoverageUS only; restrictions by state, confirmed at intakePublic availability map marks CA, MI, IN, AR, AL, SC, NC, MA, CT and NJ unavailable; confirm current patient-state and pharmacy eligibility before payment.
Brand-name accessNot confirmedCurrent GLP-1 plans describe compounded injections; a named branded prescription offer is not confirmed.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Brello Health: Brello bills three-month GLP-1 plans upfront and renews every eleven weeks; refund rights depend on clinical review, dispensing and delivery timing.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.